Filings monitor · PFE

What PFIZER INC's SEC filings said

10-Q for 2026Q3, filed 3 Nov 2026, and 2 8-Ks since. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

1. Restructuring Charges77 · importance in its document · 8-K exhibit · 3 Nov 2026
   Third-quarter 2026 restructuring charges and certain acquisition-related costs totaled $791 million, compared with $286 million in the prior-year quarter. Within that total, cost-reduction initiative charges were $742 million, compared…
2. Intangible Asset Impairments69 · importance in its document · 10-Q · 2026Q3
   For the nine months ended September 27, 2026, Pfizer’s reconciliation included a $4.325 billion adjustment for certain asset impairments. The comparable 2025 nine-month reconciliation showed a $577 million adjustment for certain asset…
3. Guidance / Outlook68 · importance in its document · 8-K exhibit · 3 Nov 2026
   Pfizer raised its full-year 2026 revenue guidance by $1.5 billion at the midpoint to $62.0–$64.0 billion, from $60.5–$62.5 billion. Adjusted diluted EPS guidance was raised and narrowed to $2.95–$3.05 from $2.80–$3.00, and includes an…
4. Operating Cash Flow Trends64 · importance in its document · 10-Q · 2026Q3
   Operating cash flow for the nine months ended September 27, 2026 increased to $8.825 billion from $6.356 billion in the prior-year period, a 39% increase. Pfizer attributed the increase mainly to the timing of ordinary-course receipts and…
5. Guidance raised60 · rule score among filings · 8-K Item 2.02 · 3 Nov 2026
   Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 3 Nov 2026

Full report · Filing on EDGAR

• Intangible Asset ImpairmentsImportance 69
  For the nine months ended September 27, 2026, Pfizer’s reconciliation included a $4.325 billion adjustment for certain asset impairments. The comparable 2025 nine-month reconciliation showed a $577 million adjustment…
• Operating Cash Flow TrendsImportance 64
  Operating cash flow for the nine months ended September 27, 2026 increased to $8.825 billion from $6.356 billion in the prior-year period, a 39% increase. Pfizer attributed the increase mainly to the timing of…
• Litigation and Legal RiskImportance 58
  For the first nine months of 2026, Pfizer recorded $1.0 billion of charges for certain legal matters, primarily product liability and other legal expenses. The comparable charges for the first nine months of 2025 were…
• Restructuring ChargesImportance 58
  Pfizer announced an additional $1.0 billion of anticipated net savings from its Realigning Our Cost Base Program, bringing expected cumulative savings to approximately $6.7 billion through 2029; the additional savings…
• Manufacturing Footprint OptimizationImportance 58 · +1 more on this subject
  In the third quarter of 2026, Pfizer announced a new phase of its Manufacturing Optimization Program, focused on network structure changes, product portfolio enhancements and operational efficiencies. The phase is…
• Revenue Performance and MixImportance 57
  Third-quarter revenue was relatively flat, while revenue excluding Comirnaty and Paxlovid increased 7% operationally; nine-month revenue also increased 7% excluding those COVID-19 products. Demand and market-share…
• Trade Policy and TariffsImportance 53
  On April 2, 2026, the U.S. Government announced Section 232 tariffs of up to 100% on imported patented pharmaceuticals and their ingredients, citing national-security concerns about supply-chain reliance. The measures,…
• Metsera Acquisition SynergiesImportance 52
  Following the November 2025 acquisition of Metsera, Pfizer expects approximately $600 million in annual cost synergies by the end of 2026. The one-time costs to generate those synergies are expected to total…
• ViiV Investment ExitImportance 48
  Pfizer completed the sale of its 11.7% investment in ViiV on March 31, 2026, during its second fiscal quarter. The transaction generated $1.875 billion in cash proceeds. The sale contributed to a $1.870 billion net…
• Drug Pricing PolicyImportance 46
  Pfizer expects continued U.S. government and state attention to drug pricing and access, including international reference pricing and Most-Favored-Nation pricing. Under the Inflation Reduction Act’s Medicare Drug…
• Product Pipeline ProgressImportance 41
  Pfizer reported 2026 U.S. approval of Veppanu (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer and U.S. and EU approvals expanding Padcev and other products into additional treatment…
• Acquired In-Process R&D ExpenseImportance 34
  Acquired in-process research and development expense declined $722 million in the third quarter and $579 million in the first nine months of 2026. The 2026 expense included a $650 million charge for an in-licensing and…

8-K filings last 12 months

• New CFO named3 Nov 2026 · 8-K Item 5.02 · Routine · rule score 35
  “On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1,…”
  Read from the attached exhibit: CFO Leadership Transition
• Guidance raised3 Nov 2026 · 8-K Item 2.02 · Flagged · rule score 60
  “Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance”
  Read from the attached exhibit: Restructuring Charges · Guidance / Outlook · Net Income and Profitability
• Results (release not read)4 Aug 2026 · 8-K Item 2.02 · Routine · rule score 20
  Read from the attached exhibit: Intangible Asset Impairments · Litigation and Legal Risk · Oncology Portfolio Growth
• CFO exit, abrupt18 Jun 2026 · 8-K Item 5.02 · Flagged · rule score 80
  “On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry…”
  Read from the attached exhibit: Management Changes
• Results (release not read)5 May 2026 · 8-K Item 2.02 · Routine · rule score 20
• Results (release not read)3 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20

Earlier reports

• 10-Q · 2026Q2filed 4 Aug 2026
  Impairment Charges · Litigation and Legal Risk · Income Tax Rate Changes

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.